Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28909093 | 0.82 | L3MBTL1 (0.68) | GSTO1ALDH1A1MAPTL3MBTL1NPSR1 | |
| SCHEMBL26567164 | 0.81 | KAT6A (0.54) | ALDH1A1LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL26567162 | 0.77 | L3MBTL1 (0.45) | GSTO1L3MBTL1ALPL | |
| SCHEMBL6488915 | 0.77 | GSTO1 (0.51) | GSTO1LMNAKMT2AHTTMEN1 | |
| SCHEMBL26567158 | 0.77 | GSTO1 (0.48) | GSTO1ALDH1A1LMNAKMT2AHTT | |
| SCHEMBL2372705 | 0.74 | MCL1 (0.62) | GSTO1ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL13855836 | 0.73 | GSTO1 (0.53) | GSTO1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL11512517 | 0.73 | MCL1 (0.61) | GSTO1ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL11512510 | 0.73 | MCL1 (0.61) | GSTO1ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL15963707 | 0.73 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | GSTO1 4295/4885ALDH1A1 2570/4885LMNA 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.